The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2506-2508 June 8, 2006 Number 23
NextNext

Tenofovir DF and Emtricitabine vs. Zidovudine and Lamivudine

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Supplementary Material
-Supplementary Material
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Gallant, J. E.
-PubMed Citation
To the Editor: Gallant et al. (Jan. 19 issue)1 report the superiority of a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz to a control regimen of zidovudine, lamivudine, and efavirenz in terms of suppression of replication of the human immunodeficiency virus (HIV). Two sources of bias compromise this conclusion: first, an open-label study design with a disproportionate number of discontinuations for reasons other than virologic failure in the control group and second, the issuance of a press release2 while the study was going on announcing the superiority of the tenofovir DF–emtricitabine regimen after an interim analysis at 24 . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.